Teva\'s Leukemia Drug SNDA Granted Priority Review By The FDA

Lisensi Anda Salah atau Anda belum memasukkan Lisensi

Source : https://finance.yahoo.com/news/teva-apos-leukemia-drug-snda-145102555.html

Teva's Leukemia Drug sNDA Granted Priority Review by the FDA
US FDA accepts Pfizer & Avillion's sNDA for Bosulif to treat patients with newly diagnosed Ph+ CML
FDA Greenlights Novo Nordisk's Rebinyn, TEVA's HALO Shines, LUCY Walks The Talk
SPRYCEL® (dasatinib) Receives FDA Priority Review for the Treatment of Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia (CML) in Chronic Phase
Teva Pharmaceutical Industries Limited (TEVA.TA)
Jazz Pharmaceuticals Is A Strong Buy With Potential FDA Approvals
BIOCRYST PHARMACEUTICALS, INC. : Biotech Industry Showing Signs of a Revival in 2017: Today's Research on BioCryst Pharmaceuticals and TG Therapeutics
7 Key FDA Decisions and Clinical Trial Results Coming in Q4
Communiqués de presse par sujet : Approbation de la FDA (Food and Drug Administration)